CN100348569C - 癌细胞中编程性细胞死亡的诱导 - Google Patents

癌细胞中编程性细胞死亡的诱导 Download PDF

Info

Publication number
CN100348569C
CN100348569C CNB028277066A CN02827706A CN100348569C CN 100348569 C CN100348569 C CN 100348569C CN B028277066 A CNB028277066 A CN B028277066A CN 02827706 A CN02827706 A CN 02827706A CN 100348569 C CN100348569 C CN 100348569C
Authority
CN
China
Prior art keywords
arh
etoac
mmol
mixture
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028277066A
Other languages
English (en)
Chinese (zh)
Other versions
CN1659130A (zh
Inventor
M·I·道森
J·A·丰塔纳
张晓坤
M·莱德
钟灵
P·霍布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stanford International Institute
Instituto de Medicina Molecular Joao Lobo Antunes
Wayne State University
Oregon State University
Sanford Burnham Prebys Medical Discovery Institute
US Department of Veterans Affairs
Original Assignee
Stanford International Institute
Instituto de Medicina Molecular Joao Lobo Antunes
Wayne State University
Oregon State University
Sanford Burnham Prebys Medical Discovery Institute
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26989041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100348569(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stanford International Institute, Instituto de Medicina Molecular Joao Lobo Antunes, Wayne State University, Oregon State University, Sanford Burnham Prebys Medical Discovery Institute, US Department of Veterans Affairs filed Critical Stanford International Institute
Publication of CN1659130A publication Critical patent/CN1659130A/zh
Application granted granted Critical
Publication of CN100348569C publication Critical patent/CN100348569C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
CNB028277066A 2001-11-30 2002-12-02 癌细胞中编程性细胞死亡的诱导 Expired - Fee Related CN100348569C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33408101P 2001-11-30 2001-11-30
US60/334,081 2001-11-30
US40625202P 2002-08-26 2002-08-26
US60/406,252 2002-08-26

Publications (2)

Publication Number Publication Date
CN1659130A CN1659130A (zh) 2005-08-24
CN100348569C true CN100348569C (zh) 2007-11-14

Family

ID=26989041

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028277066A Expired - Fee Related CN100348569C (zh) 2001-11-30 2002-12-02 癌细胞中编程性细胞死亡的诱导

Country Status (7)

Country Link
US (2) US7053071B2 (https=)
EP (1) EP1456165A1 (https=)
JP (1) JP2005516908A (https=)
CN (1) CN100348569C (https=)
AU (1) AU2002346620A1 (https=)
CA (1) CA2468745A1 (https=)
WO (1) WO2003048101A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7632972B2 (en) * 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
US7709465B2 (en) 2006-05-19 2010-05-04 The Board Of Trustees Of The University Of Illinois Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
LV13735B (en) 2006-12-28 2008-09-20 Vjaceslavs Tribulovics Method for manufacturing substituted adamantylarylmagnesium chalogenides
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
US20100130598A1 (en) * 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
AU2010210403B2 (en) 2009-02-09 2016-07-28 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
CN102892755A (zh) 2009-12-23 2013-01-23 韦恩州立大学 治疗性化合物
ES2361432B9 (es) 2011-03-18 2012-04-24 Biofungitek, Sociedad Limitada Composición fitosanitaria que comprende aceites esenciales potenciadores de la actividad antifúngica.
US10820597B2 (en) 2011-03-18 2020-11-03 Biofungitek, S.L. Phytosanitary composition comprising essential oils that potentiate antifungal activity
EP2817292B1 (en) * 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
CN116350622A (zh) * 2023-04-04 2023-06-30 广西中医药大学 Pycnidione在制备抗前列腺癌药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
JP3537065B2 (ja) * 1996-07-01 2004-06-14 キヤノン株式会社 電子写真感光体、プロセスカートリッジ及び電子写真装置
IL127946A0 (en) 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
US6462064B1 (en) * 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
WO1998037053A1 (en) * 1997-02-25 1998-08-27 Galderma Research & Development, S.N.C. Identification of a unique receptor specific for a particular retinoid inducing cellular apoptosis
FR2776657B1 (fr) * 1998-03-31 2000-05-26 Cird Galderma Composes bicycliques-aromatiques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
GB9927056D0 (en) * 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
EP1278734A2 (en) * 2000-04-24 2003-01-29 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
IL157740A0 (en) 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.

Also Published As

Publication number Publication date
US7053071B2 (en) 2006-05-30
USRE42700E1 (en) 2011-09-13
WO2003048101A1 (en) 2003-06-12
EP1456165A1 (en) 2004-09-15
AU2002346620A1 (en) 2003-06-17
CA2468745A1 (en) 2003-06-12
JP2005516908A (ja) 2005-06-09
US20030176506A1 (en) 2003-09-18
CN1659130A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
CN100348569C (zh) 癌细胞中编程性细胞死亡的诱导
DE69333771T2 (de) Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die Behandlung von Hyperplasie und andere Krankheiten
CN1193996C (zh) 可用作抗氧剂和5－脂氧合酶抑制剂及非甾体类抗炎药的抗炎非甾体类羧酸酯和酰胺
CN104936591B (zh) 促红细胞生成素表达增强剂
CN102361855B (zh) 囊性纤维化跨膜传导调节因子的调节剂的制备方法
JP2008531689A (ja) 血栓症の治療のための第ｘｉ因子及び第ｉｘ因子の阻害剤としての２−［イソキノリン−３−カルボニル）アミノ］−プロピオン酸誘導体
UA124708C2 (uk) Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора
JPH08505847A (ja) シクロアルキルアミンビス−アリールスクアレンシンターゼインヒビター
JP2000502072A (ja) 平滑筋弛緩および／または肥満細胞安定化および／または抗炎症作用を有するインダンダイマー（二量体）化合物
JP2007506758A (ja) ４−（１−ベンゾフラン−３−イル−メチリデンアミノオキシ））−安息香酸誘導体および線溶系の障害、血栓症または心臓疾患の治療用のｐａｉ−１阻害剤としての関連化合物
DE4327365A1 (de) Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
JP2008531558A (ja) 新規なリポオキシゲナーゼ阻害剤
JPH03503280A (ja) 新規ＨＭＧ‐ＣｏＡレダクターゼ阻害剤
CN115916740A (zh) 拟甲状腺素药
JP2018505196A (ja) 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン
JP2019505548A (ja) Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用
BR112021003660A2 (pt) compostos úteis como moduladores de autofagia mediada por chaperonas
JP2512656B2 (ja) トロポロン誘導体ならびに虚血性疾患を予防および治療するためのその薬剤組成物
TW202237073A (zh) 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
WO2022223778A1 (en) Citraconic acid and derivatives thereof for use as a medicament
JP3990632B2 (ja) ベンゾフラン誘導体及びそれを含有する医薬組成物
JP2007507450A (ja) 抗炎症剤としての置換されたペンタノール、これらを生成する方法、およびこれらの使用
JP2003034638A (ja) アテローム性動脈硬化症の治療のための安息香酸置換ベンゾピラン
CN102381972A (zh) 带有酯结构末端的丙泊酚羟基酸酯类化合物及其制备方法和应用
CA2339094A1 (en) Macrophage scavenger receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee